The efficacy of DPP4 inhibitor in heart failure patients with type 2 diabetes.

The efficacy of DPP4 inhibitor in heart failure patients with type 2 diabetes. - The efficacy of DPP4 inhibitor in heart failure patients.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014069

Enrollment

Registered

2014-05-26

Start date

2014-02-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure patients with type 2 diabetes

Interventions

DPP4 inhibitor conventional DM therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: heart failure patients with type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: 1.Allergy to DPP4 inhibitor 2.poorly-controled diabetes mellites (HbA1c over 8.0%) 3.under incretin related drug therapy 4.under insulin and sulphonylurea therapy 5.critical arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, long QT syndrome, 2 to 3 degree AV block etc) 6.acute coronary syndrome 7.CABG or PCI planned within 6 months 8.renal dysfunction (Cre over 2.0mg/dl or CCr under 30 ml/min) 9.severe liver dysfunction or any life-threatening acute diseases 10.pregnacy 11.poor prognosis 12.alcohol or drug addiction 13.lack of written informed consent 14.other ineligibility judged by the doctor in charge

Design outcomes

Primary

Measure	Time frame
change of NT-proBNP	—

Countries

Japan

Contacts

Public ContactMasayoshi Suda

Niigata University Medical & Dental Hospital Department of Cardiovascular Biology and Medicine

m-suda@med.niigata-u.ac.jp025-227-2185

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026